title: How Keytruda’s Subcutaneous FDA Approval and Extended Patent Could Shape Merck’s (MRK) Investment Trajectory
source: Yahoo
date: 2025-10-13
url: https://finnhub.io/api/news?id=edcbe5441b6fc9964b04357c992c00357d769273e2b9e663a76754df83ebdb72
In early October 2025, Merck announced FDA approval for a subcutaneous version of Keytruda and shared positive Phase 3 trial outcomes for both Keytruda in several cancer types and Winrevair in pulmonary arterial hypertension, with new research presented at the ESMO Congress in Berlin. The subcutaneous Keytruda formulation extends the drug's patent protection beyond 2028 while enhancing patient and provider convenience, a significant move to reinforce Merck’s oncology leadership amid stiff...
